Search for new immunotherapies for bone cancer
25 augustus 2026
A major European research project is set to explore innovative treatments for Ewing sarcoma. On 1 September, the THEODORA project will launch at the Princess Máxima Center, led by Institut Curie in Paris. Together with other European partners, we will work on new forms of targeted immunotherapy for children and young adults with this rare and aggressive form of bone cancer.
Young people with Ewing sarcoma are treated with a combination of chemotherapy, surgery and radiotherapy. For some patients, this treatment is effective. However, if the disease comes back or has already spread, the outlook remains poor. In addition, many young people experience long-term effects of treatment that impact their health and quality of life.
A new target
Researchers at Institut Curie have identified unique proteins that are found only in Ewing sarcoma tumor cells. These so-called neoantigens form the basis for the search for new, highly targeted immunotherapies within the THEODORA project.
Cell therapy
‘We will investigate a cell therapy that directs immune cells specifically towards Ewing sarcoma tumor cells,’ says Dr Miranda Dierselhuis, who leads the project at the Princess Máxima Center. ‘We will manufacture this immunotherapy ourselves at the Princess Máxima Center for all children and young people participating in the study, both in the Netherlands and at the other participating centers across Europe.’
New hope
Dr Amaury Leruste, pediatric oncologist and researcher at Institut Curie, is the overall coordinator of the THEODORA project. He says: ‘This large-scale European project opens up new hope for young patients with Ewing's sarcoma by speeding up the development of more precise and more effective treatments against this rare and aggressive tumor.’
The THEODORA project brings together Institut Curie (Paris), the Princess Máxima Center, Hopp Children’s Cancer Center KiTZ (Heidelberg) and Gustave Roussy Institute (Paris), with funding from the European Union and Fight Kids Cancer. The overall project starts this September; the clinical trial is expected to open in 2028.
For professionals
The THEODORA project consists of two components. The largest part, funded through a Horizon Europe grant, focuses on the development of T-cell receptor therapy (TCR-T). In this approach, patients’ T cells are engineered to recognize and attack tumor cells carrying the specific Ewing antigen. THEODORA also includes a second clinical study investigating therapeutic vaccination against Ewing sarcoma. This vaccination study, THEODORA-B, recently received additional funding from Fight Kids Cancer.
Manufacturing and PROMs
The Princess Máxima Center contributes to THEODORA in several important ways. In addition to manufacturing the TCR cell product within the Cell and Gene Therapy Unit for participating treatment centers, the PROM Facility will systematically assess how patients experience the treatment and its impact on their quality of life. Information from these patient-reported outcome measures (PROMs) will be used both for research purposes and to directly inform clinical care.
The first phase of the THEODORA project will focus on further development, manufacturing and preparation for the clinical studies. The first clinical trial of the T-cell receptor therapy is expected to begin in 2028.
Dark proteome
The targets for both the TCR-T therapy and the vaccine are derived from the so-called dark proteome: protein products produced from regions of DNA that have largely been overlooked until now. Researchers in the Van Heesch group collaborated with colleagues at Institut Curie and KiTZ Heidelberg within the EU CAN KIDS alliance to identify a large set of vaccine targets for THEODORA-B.
‘We identified dozens of ‘dark antigens’ that are present in almost all children with the EWSR1-FLI1 fusion protein, a hallmark of Ewing sarcoma,’ says research group leader Dr Sebastiaan van Heesch. ‘THEODORA will be the first clinical trial in children to direct the immune system against microproteins from the dark proteome.’
The study also aligns closely with the objectives of the Cancer Grand Challenge program in which the Van Heesch group is involved. A central aim of that collaboration is to translate discoveries from the dark proteome into clinical applications.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.